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Background: Oct4 and Nanog are key regulatory genes that maintain the pluripotency and self-renewal properties
of embryonic stem cells. We previously reported that the two stemness markers were tightly associated with cancer
progression and poor outcomes of hepatocellular carcinoma. In this study, we demonstrate that coexpression
of Oct4/Nanog modulates activation of signal transducer and activator of transcription 3 (Stat3), an oncogenic
transcription factor that is activated in many human malignancies including hepatocellular carcinoma (HCC), as well
as the expression of Snail, a key regulator implicated in epithelial-mesenchymal transition and tumor metastasis.
Methods: Oct4 and Nanog were ectopic expressed in MHCC97-L cell lines via lentiviral gene transfection. The
stemness characteristics including self-renewal, proliferation, chemoresistance, and tumorigenicity were assessed.
The effect of coexpression of Oct4 and Nanog on epithelial-mesenchymal transition change, and the underlying
molecular signaling was investigated.
Results: Ectopic coexpression of Oct4 and Nanog empowered MHCC97-L cells with cancer stem cell (CSC) properties,
including self-renewal, extensive proliferation, drug resistance, and high tumorigenic capacity. Significantly, Oct4
and Nanog encouraged epithelial-mesenchymal transition change contributing to tumor migration, invasion/
metastasis in vitro and in vivo. Following molecular mechanism investigation indicated Oct4/Nanog-regulated
epithelial-mesenchymal transition change through Stat3-dependent Snail activation. Moreover, silencing Stat3
abrogates Oct4/Nanog-mediated epithelial-mesenchymal transition (EMT) change and invasion/metastasis in HCC.
Conclusions: We delineate Oct4 and Nanog initiate stem cell characteristics in hepatocellular carcinoma and
promote epithelial-mesenchymal transition through activation of Stat3/Snail signaling. Our findings propose Stat3/
Snail pathway as a novel therapeutic target for the treatment of progression and metastasis of HCC with CSC-like
signatures and epithelial-mesenchymal transition phenotype.
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Hepatocellular carcinoma (HCC) is one of the most
malignant tumors worldwide, and the majority of HCC-
related deaths occur due to frequent intrahepatic spread
and extrahepatic metastasis [1]. Despite enormous pro-
gress has been made in the treatment of HCC, the mor-
tality rate remains high. A better understanding of the
biology of the tumors would have a major impact on the
management of the disease.
The major advance of tumor biology in recent years
has been the discovery of the cancer stem cells (CSCs).
CSCs are reported to have inherently greater tumor-
initiating potential, which is implicated in tumor relapse,
driving primary tumor growth as well as the seeding and
establishment of metastases [2]. To date, the existence
of CSCs has been demonstrated in a wide variety of malig-
nancies including breast cancer, leukemia, glioblastoma,
liver carcinoma, and so on [3-6]. CSCs theory opens up
new possibilities of generating novel targets, diminishing
resistance to chemoradiation, improving therapeutic effi-
cacy, and improving patient outcome.
It is generally proposed that cancer stem cells originate
either from adult stem cells that have lost control of
proliferation, or progenitor cells that have acquired the
ability to self-renew. However, several studies seem to
support the theory that CSCs arise from differentiated
tumor cells that have undergone a process of dedifferen-
tiation to become more stem-like. For example, it has
been demonstrated that differentiated breast cancer cells
that underwent epithelial-mesenchymal transition (EMT)
were found to exhibit a more CSC-like phenotype [7]. Evi-
dence from other studies also indicated that the CSC-like
cells might be generated with processes that are related to
activation of the EMT, which impacts cell differentiation
and tumor metastatic potential [8]. Thus, CSC biology
and the EMT are thought to be mechanistically corre-
lated and may be key components of cancer progression
and metastasis [7]. An in-depth investigation of cross-
talk of cancer stemness with EMT is essential to a better
understanding of tumor progression from a stem cell
model perspective.
Oct4 and Nanog are transcription factors essential for
maintaining stem cell phenotypes. Oct4, a homeobox-
containing transcription factor, was originally shown to
be one of the essential factors regulating pluripotency
and self-renewal properties in embryonic stem cells [9].
Nanog, a downstream target of Oct4, expressed in em-
bryonic pluripotent stem cells, contributes to cell fate
determination of the pluripotent inner cell mass during
embryonic development [10]. Several lines of evidence
have suggested that expression of Oct4 and Nanog is
closely related to tumorigenesis, tumor metastasis, and
distant recurrence after treatment [11,12]. In our previ-
ous study [13], we have identified that expression ofOct4 and Nanog are highly related to metastatic poten-
tial of HCC cells. Moreover, coexpression of Oct4 and
Nanog is a strong independent predictor of tumor
recurrence and unfavorable outcome in HCC patients.
Based on these findings, CSC theory as well as EMT
program, we propose a hypothesis that overexpression
of stem cell markers Oct4 and Nanog, which maintain
self-renewal and proliferation in embryonic stem cells,
may also maintain HCC cell self-renewal, proliferation,
metastasis through initiating CSC-like properties, and
promoting EMT. To this end, we investigate the role of
coexpression of Oct4 and Nanog in CSC-like traits, EMT,
and metastasis in HCC. We illustrate that coexpression of
Oct4 and Nanog initiates stem cell characteristics in HCC
and promotes epithelial-mesenchymal transition through
activation of Stat3/Snail signaling.
Results
Coexpression Oct4 and Nanog enhances cancer stem-like
properties in HCC cells
To define the role of Oct4 and Nanog in stem-like prop-
erties, we generated stable cell lines (97 L-ON) from
97 L human HCC cells using lentiviral infection system
with plasmid vectors encoding Oct4 and Nanog cDNA.
An empty vector-transfected control (97 L-Ctrl) was
produced simultaneously. The exogenously expressed
Oct4 and Nanog in HCC stable clones were confirmed
by Western blot (Figure 1A) and quantitative real-time
PCR (Figure 1B).
We examined the expression of stem cell markers in
our 97 L-ON cells. Quantitative PCR analysis showed
markedly elevated expression of stem cell-associated genes,
including CD133, BMi-1, and aldehyde dehydrogenase 1
(ALDH1), which were found in 97 L-ON cells (Figure 1E)
but not in 97 L-control cells.
Given that self-renewal is a hallmark of CSCs, we
performed colony formation ability assay and sphere-
forming ability assay to investigate the role of Oct4 and
Nanog in promoting self-renewal property in HCC cells.
As shown in Figure 1D, 97 L-ON cells possessed an
increased ability to form colonies after culture in compari-
son with the control group (mean colony numbers: 68 ±
19 vs. 202 ± 38, P = 0.002). In sphere-forming ability assay,
few non-adherent spheres were observable in 97 L-ON
cells after in vitro culture for 1 week and these continued
to expand for 2 to 3 weeks in serum-free media. Signifi-
cant difference was found in speroid body formation be-
tween 97 L-Ctrol cells and 97 L-ON cells (Figure 1F, 4 ± 1
vs. 18 ± 3, P = 0.01). These results indicated that coexpres-
sion of Oct4 and Nanog promoted the tumorigenicity of
HCC cells by enhancing their self-renewal abilities.
Resistance to chemotherapy is another important char-
acteristic of CSCs. The 97 L-ON cells displayed increased
resistance to cisplatin (DDP) than 97 L-control cells
Figure 1 Oct4/Nanog overexpression enhances cancer stem-like property and resistance ability in 97 L cell line. (A, B) MHCC97L cells
were infected with lentiviral vectors encoding cDNA of Oct4 and Nanog (97 L-ON) or a control empty vector (97 L-Ctrl). 97 L-ON cells were
analyzed by Western blot and real-time RT-PCR for Oct4 and Nanog expression (*P < 0.05, **P < 0.01). (C) Cell proliferation of 97 L-ON and 97
L-Ctrol cells by CCK-8 assay analysis (*P < 0.05). Proliferation is significant promoted in 97 L cell lines after overexpression of Oct4 and Nanog
genes. (D) 97 L-ON cells and 97 L-Ctrl cells were subjected to sphere formation assay. The sphere formation was photographed (left) and
quantified (right). Colony formation of 97 L-ON cells was increased significantly in comparison with 97 L-Ctrol cells (68 ± 19 vs. 202 ± 38, P = 0.002).
(E) The mRNA expression of stem cell markers (CD133, CD44, ALDH1, BMi-1, ABCG2, MDR1) between 97 L-ON cells and 97 L-Ctrol cells was analyzed
by real-time RT-PCR, *P < 0.05, **P < 0.01, ***P < 0.001 (F) 97 L-ON cells formed the self-renewing spheroid bodies (left). The spheroid body formation
rate of 97 L-ON cells was higher than that of 97 L-Ctrol cells (right, 18 ± 3 vs. 4 ± 1, P = 0.01). (G) 97 L-ON cells were treated with cisplatin (0.1, 0.25, 0.5,
1.0, 2.5, 5, 10 μmol/L) for 48 h. Cell survival was determined by CCK-8 assay (*P < 0.05).
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the ABC family of multidrug resistant genes ABCG2 and
MDR1 were highly enhanced in 97 L-ON cell (Figure 1E).
Coexpression of Oct4 and Nanog promotes EMT changes
and increases HCC cell proliferation, invasion, and
metastasis in vitro
After exogenously expressing Oct4 and Nanog in 97 L
cells, a typical morphological change was noted in 97 L-
ON cells. The cellular morphology was converted to a
spindle-shaped, fibroblast-like morphology, as compared
with control cell (Figure 2A). This phenomenon suggested
that Oct4 and Nanog were involved in the EMT of HCC.
We further investigated putative EMT-related markers,
such as E/N-cadherin, Vimentin, Snail, Slug, and Twist byreal-time PCR and Western blot. The results revealed that
overexpression of Oct4 and Nanog led to a significant in-
crease in the mesenchymal genes, N-cadherin, Snail, and
Vimentin and a decrease in the epithelial gene E-Cadherin
at both mRNA and protein levels (Figure 2B). These ob-
servations indicated that coexpression of Oct4 and Nanog
could induce the EMT of HCC.
Since the acquisition of mesenchymal properties is
associated with increased migratory and invasive proper-
ties, we investigated the effect of Oct4 and Nanog on
HCC proliferation, invasion, and metastasis. As showed
in Figure 1C, CCK-8 assay revealed that cell proliferation
was significantly promoted by coexpression of Oct4 and
Nanog (P < 0.001). We further determined the roles of
Oct4 and Nanog in HCC migration and invasion. Wound
Figure 2 Overexpression of Oct4 and Nanog promotes EMT and proliferation, migration, and invasion in HCC Cells. (A) 97 L cells
undergo dramatic morphologic changes into mesenchymal, fibroblast-like phenotype after treatment with ectopic Oct4 and Nanog expressions.
(B) Alterations in EMT genes with overexpression of Oct4 and Nanog. Quantitative RT-PCR and immunoblot analysis of epithelial and mesenchymal
mRNA and proteins expression in 97 L-ON cells and 97 L-Ctrol cells. Significant increases in the mesenchymal genes, N-cadherin, Snail, and Vimentin
and decrease in the epithelial gene E-Cadherin were found in 97 L-ON cells at both mRNA and protein levels (* P < 0.05,** P < 0.01). (C) The wound
healing assay showed that the closure of 97 L-Ctrol cells were significantly slower than that of 97 L-ON cells (P = 0.001). (D) In transwell assay, cells that
invaded through the Matrigel-coated inserts were stained, counted, and photographed under a light microscope at × 100 magnification. Quantification
invasion assay indicated that the number of 97 L-ON cells that passed through the Matrigel was more than that of 97 L-Ctrol cells (179 ± 23 vs.
35 ± 13, P < 0.001).
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was significantly slower than that of 97 L-ON cells
(Figure 2C, P = 0.001). Transwell invasion assay indicated
that the number of 97 L-ON cells that passed through the
Matrigel was much more than that of 97 L-Ctrol cells
(179 ± 23 vs. 35 ± 13, P < 0.001, Figure 2D). These results
showed that endogenous expression of Oct4 and Nanog
was associated with HCC invasion and metastasis in vitro.
Coexpression of Oct4 and Nanog promotes tumorigenic
and metastatic abilities in vivo
Based on the in vitro findings described above, we exam-
ined the effect of Oct4 and Nanog on tumor growth and
metastasis in vivo. Xenografts in nude mice were estab-
lished by subcutaneous injection of 97 L-ON cells and97 L-Ctrol cells into nude mice as described in the
Methods section. Tumor size was monitored every 3 days
with a caliper. The tumor growth of the xenografts derived
from the 97 L-ON cells was comparable to that of the
97 L-Ctrol cells, showing a marked increase in tumor
volume (P < 0.05, Figure 3A, B). In addition, the final mean
tumor weight of the 97 L-ON group was significantly heav-
ier than that of the 97 L-Ctrol group (P = 0.001, Figure 3C),
which indicated that the overexpression of Oct4 and
Nanog promoted growth of 97 L cells in vivo.
A serial dilution experiment was performed to evaluate
the in vivo tumorigenecity of 97 L-ON and 97 L-Ctrol cells.
Nude mice were injected with different number of cells as
indicated. 97 L-ON, but not 97 L-Ctrol, generated tumors
with the cell number as low as 5 × 103 cells (Table 1).
Figure 3 Overexpression Oct4 and Nanog promotes proliferation and metastasis of HCC in vivo. (A) 97 L-Ctrol cells and 97 L-ON cells
were injected subcutaneously into the right flank of nude mice. Six weeks after implantation, 97 L-ON cells produced larger tumors than control
cells. (B) The tumor size from each group was measured every 3 days and weighed before dissection. There are significant differences in tumor
size between the two groups (all P < 0.05). (C) The average weight of the 97 L-ON tumors was significantly increased compared with the 97
L-Ctrol tumors (P = 0.001). (D) The characteristic pictures of intrahepatic invasion (top, H & E staining, black arrows point to the invasive nodules),
vascular invasion (middle, CD31 staining, black arrows point to the vascular invasion), and lung metastasis (bottom, H & E, black arrows point to
the metastatic nodules in lung). (E) Number of disseminated tumor nodules in liver. More intrahepatic disseminated tumor nodules can be found
in the 97 L-ON group (P = 0.03). (F) Number of metastatic tumor nodules in lung. More metastatic nodules in lung can be found in the 97 L-ON
group (P = 0.018).
Table 1 In vivo serial tumorigenicity experiments of 97
L-Ctrol cells and 97 L-ON cells
Cell type Cell number injected Tumor incidence Latency (days)
97 L-Ctrol 5*103 0/6 NA
5*104 0/6 NA
5*105 1/6 24
97 L-ON 5*103 1/6 22
5*104 2/6 14 ± 3
5*105 4/6 12 ± 2
N/A: results not available.
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invasion and metastasis in vivo, we established an ortho-
topic xenograft model in nude mice. After 42 days,
97 L-ON xenograft tumors displayed conspicuous intra-
hepatic invasion and vascular invasion, compared with
97 L-Ctrol cells (Figure 3D). Then, the incidences of
liver dissemination and lung metastasis in the 97 L-ON
model and 97 L-Ctrol model were evaluated. As expected,
the numbers of metastatic foci in liver (Figure 3E, P =
0.001) and lung (Figure 3F, P = 0.002) of recipient mice
were significantly increased by ectopic overexpression of
Oct4/Nanog. Together, these findings demonstrated coex-
pression of Oct4 and Nanog promotes tumorigenic and
metastatic abilities in nude mice Xenograft tumor models.
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activation of Stat3 pathway
Previously, we have observed that 97 L-ON cells contained
a mesenchymal-like phenotype, whereas the 97 L-Ctrol
cells stayed in their original epithelial-like morphology.
The regulation of EMT involves complex signaling path-
ways mainly including TGF-β, Wnt/β-catenin, Stat3,
Notch, and Hedgehog pathway [14], leading to enhanced
tumor invasion and metastasis. It has been reported that
Oct4 can regulate signal transducer and activator of tran-
scription 3 (Stat3) expression in embryonic stem cells
[15], while a functional cooperation between Nanog and
p-Stat3 translocation was also implied in breast and ovar-
ian cancer [16]. We asked whether Oct4 functions with
Nanog in regulating EMT by activation of Stat3 pathway.Figure 4 Oct4 /Nanog regulates EMT by activating Stat3 pathway. (A)
L-Ctrol cells and 97 L-ON cells. 97 L-ON cells expressed significantly higher
p-Stat3Y-705 (total protein and nucleus protein) expression in 97 L-ON-Scram
cells. (C) Expression of Stat3, p-Stat3 (Y705) proteins, Jak1, p-Jak1, Jak2, p-Ja
expression on stat3 expression, activation, and translocation. Western blot a
p-Stat3 (Y705), and p-Jak1, p-Jak2, p-Scr protein expression but increased p
of phospho-Stat3 induced by Nanog. (E) Immunostaining of Nanog (Alexa
Fluor®568-labeled anti-Nanog, red color). Colocalization of Nanog and p-Sta
of Nanog promoted p-Stat3 nuclear translocation in immunofluorescence a
L-Ctral cells. After overexpression of Nanog, staining of p-Stat3 protein (greWe examined the expression levels of Stat3, p-Stat3
(Y705), and p-Stat3 (S727) expression in 97 L-ON cells
and 97 L-Ctrol cells (Figure 4A). The results showed
that 97 L-ON cells expressed higher amounts of p-Stat3
(Y705) than 97 L-Ctrol cells.
To test the independent role of Oct4 or Nanog in
Stat3 activation in 97 L-ON cells, we treated the 97 L-ON
cells with either Nanog shRNA and/or OCT4 shRNA and
examined the effect of Oct4/Nanog knockdown on Stat3
pathway in vitro. As shown in Figure 4B, knockdown ex-
pression of Oct4 significantly reduced the expression of
total tyrosine phosphorylated Stat3 (p-Stat3Y705). While
knockdown Nanog had no effect on total p-stat3, it re-
duced p-stat3 in nucleus (p-Stat3Y705). Double-knockdown
Oct4/Nanog significantly decreased p-Stat3 protein inStat3, p-Stat3 (Y705), and p-Stat3 (S727) protein expression in 97
amounts of stat3 and p-Stat3 (Y705) than 97 L-Ctrl cell lines. (B) Stat3,
ble, 97 L-ON-shOct4, 97 L-ON-shNanog, 97 L-ON-double knockdown
k2 in 97 L-Ctrol, 97 L-shOct4, and 97 L-Oct4 cells. (D) Effect of Nanog
nalysis revealed that Nanog had no effect on Stat3 protein, total
-Stat3 (Y705) amounts in nucleus, which indicated nuclear translocation
Fluor®488-labeled anti-Nanog, green color) and p-Stat3 (Alexa
t3 (Y-705) is shown as yellow in the merged image. (F) Overexpression
nalysis. p-Stat3 (Y-705) was localized in cytoplasm and nucleus in 97
en) was significantly increased in the nucleus of 97 L-Nanog cells.
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Oct4 might upregulate the total p-Stat3 (Y705) protein
level in HCC and Nanog might regulate p-Stat3 nuclear
localization.
To further investigate the role of Oct4 in regulation
of Stat3, we established 97 L-shOct4 cells transfected
with Oct4 shRNA to downregulate endogenous Oct4
expression and 97 L-Oct4 transfected with plasmid to
upregulate Oct4, with empty plasmid as control. As ex-
pected (Figure 4C), silencing of Oct4 induced a reduc-
tion in p-Stat3 (Y705) protein, whereas overexpression
of Oct4 increased the expression of p-Stat3 (Y705). To
elucidate the exact mechanism by which Oct4 regulates p-
Stat3, we examined Stat3 upstream kinase molecules Jak1,
p-Jak1, Jak2, p-Jak2, Scr, and p-Scr. The results showed
that overexpression of Oct4 augmented the expression
of Stat3 upstream kinases p-Jak2 expression. Then, we
treated 97 L-Oct4 cells with AZD1480 (AstraZeneca,
Waltham, MA, USA), a Jak2-specific inhibitor which
blocks Stat3 activation and its downstream signaling.
Western blot analysis showed inhibition of Jak2 abro-
gated Oct4-induced phosphorylation of Stat3 and its
downstream genes CyclinD1 and Survivin (Additional
file 1: Figure S1). These results clearly indicated that
Oct4 mediates Stat3 activation through Jak2 pathway.
We then assessed the effect of Nanog expression on
Stat3 activation and translocation. 97 L-sh Nanog cells
transfected with Nanog shRNA to downregulate endogen-
ous Nanog expression and 97 L-Nanog transfected with
plasmid to upregulate Nanog were established. As ex-
pected, we found an increase of p-Stat3 in the nucleus of
97 L-Nanog cells and a decrease of p-Stat3 in the nucleus
of 97 L-sh Nanog cells. No significant changes were found
in total p-Stat3 protein and its upstream kinases Jak1,
p-Jak1, Jak2, p-Jak2, Src, and p-Src expression (Figure 4D).
Then, we used immunofluorescence to assess the co-
location of Nanog and p-Stat3 (Y705) in 97 L-Nanog cells.
As showed in Figure 4E, both red fluorescence and green
fluorescence were accumulated at the nucleus of cell clus-
ters and overlapped as yellow fluorescence, indicating the
co-location of Nanog and p-Stat3. Figure 4F showed that
in 97 L-Ctrol cells, p-Stat3 was predominantly found both
in cytoplasm and nucleus, whereas it appeared to be
primarily retained within the nucleus in 97 L-Nanog cells,
which indicated that overexpression of Nanog in 97 L cells
promoted p-Stat3 (Y705) translocation into the nucleus.
In order to examine whether Nanog interacts with
p-Stat3 (Y705) directly in the nucleus of HCC cells, we
analyzed the anti-Nanog-mediated immunoprecipitates
from nuclear extracts by immunoblotting with anti-p-
Stat3 (Y705), or anti-Nanog antibody, respectively, in 97 L
cell lines. Our results demonstrated a measurable amount
of Nanog, p-Stat3 complexes (Figure 5A) in the nuclear
fractions of 97 L cell lines. Furthermore, the same resultswere also confirmed in another HCC cell lines (HepG2
cell lines, Additional file 2: Figure S2). These findings sug-
gested that Nanog is capable of forming a complex with
p-Stat3 (Y705) in cell line in an independent manner.
Oct4/Nanog-mediated Stat3 activation regulates snail
expression in 97 L-ON cells
Our previous experimental study indicated that overex-
pression of Oct4/Nanog significantly increased the expres-
sion of Snail, but not Slug or Twist, at both mRNA and
protein levels in 97 L-ON cells (Figure 1B). It has also
been reported that the activation of Stat3 induced EMT
through Snail activation in head and neck tumor [17]. To
determine whether Oct4/Nanog-promoted Snail expres-
sion is mediated by Stat3 phosphorylation, we treated
97 L-ON cells with S31-201 [18], a specific Stat3 inhibitor,
effectively inhibited Stat3 phosphorylation, dimerization,
and translocation to nucleus. As showed in Figure 5B,
Oct4/Nanog-induced Snail expression was significantly
inhibited by S3I-201. To further confirm these results, we
examined the effects of shRNA-mediated Stat3 knock-
down on Snail expression. Indeed, knockdown of Stat3
dampened Oct-4/Nanog-induced expression of Snail ex-
pression in 97 L-ON cells (Figure 5C).
Since knockdown of Stat3 expression greatly reduced
snail mRNA levels, we assessed whether Stat3 inhibited the
activity of the Snail gene promoter by chromatin immuno-
precipitation (ChIP) assay. p-Stat3 antibody or IgG serum
was conducted to immunoprecipitate DNA-protein com-
plexes from 97 L-ON cells in which Stat3 is constitutively
active. According to bioinformatic prediction, there are
two Stat3 consensus binding sites in the mouse Snail pro-
moter (from −592 to −301 bp, Figure 5D). Compared with
97 L-Ctrol cell, p-Stat3 binding on the Snail promoter were
significant enriched in 97 L-ON cell (Figure 5E). These
results showed that Stat3 activation is involved in Oct4/
Nanog regulation on Snail expression.
Silencing Stat3 abrogates Oct4/Nanog-mediated EMT
changes and invasion/metastasis of HCC
Because Stat3 was correlated with Oct4/Nanog-medi-
ated EMT, we investigated the impact of Stat3 knock-
down in EMT changes and invasion/metastasis of 97
L-ON cells. We found that after silencing Stat3, 97 L-ON
cell underwent morphologic change, from mesenchymal
phenotype to epithelial phenotype (Figure 6A). Accom-
panied with morphologic change, significant decreases in
the mesenchymal genes, N-cadherin, Snail, and Vimen-
tin and increase in the epithelial gene E-Cadherin were
found in 97 L-ON-shStat3 cells in Western blot analysis
(Figure 6D). Furthermore, the numbers of migration
and invasion of 97 L-ON-ShStat3 cells were significantly
lower than 97 L-ON-Scramble cells (Figure 6B, C). Then,
we investigated the effects of Stat3 knockdown on liver
Figure 5 Oct4/Nanog-mediated Stat3 activation regulates snail expression in 97 L-ON cells. (A) Association of Nanog with p-Stat3 in the
nucleus of 97 L cell line. Equal amounts of protein were immunoprecipitated (IP) with an anti-Nanog monoclonal antibody or anti-p-Stat3-Y705
antibody and were immunoblotted to detect Nanog or p-Stat3 (Y-705). Normal mouse IgG was used as a control antibody. (B) Oct4/Nanog-
induced Snail expression was significantly inhibited by a specific Stat3 inhibitor S3I-201 (10 μM for 48 h). (C) Knockdown of Stat3 reversed
Oct-4/Nanog-induced overexpression of Snail in 97 L-ON cells. (D) Schematic representation of structure of Snail promoter reign. Grey rectangle
represented putative Klf4 binding sites predicted using MatInspector. Black arrows (thin) depicted the location of the forward and reverse primers
used for PCR amplification from immunoprecipitated DNA fragments. (E) Chromatin immunoprecipitation (ChIP) analysis of p-Stat3 enrichment in
Snail promoter. A p-Stat3 antibody or IgG serum was conducted to immunoprecipitate DNA-protein complexes from 97 L-ON cells with p-Stat3
overexpression. IgG was used for a negative control. Binding of p-Stat3-containing transcription complex on the Snail promoter was enriched in
97 L-ON cells, compared with 97 L-Ctrol cell.
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Consistent with those in vitro findings, 97 L-ON-shStat3
knockdown xenograft tumors displayed less liver dissem-
ination and lung metastasis in nude mice compared with
97 L-ON-Scramble tumors (Figure 6E, F). All these find-
ings demonstrated that silencing Stat3 expression abro-
gated Oct4/Nanog-mediated EMT change and invasion/
metastasis of HCC.
Discussion
Previously, we have demonstrated that Oct4 and Nanog
are coexpressed and significantly upregulated in HCC pa-
tients with early recurrence/metastasis and poor outcomes
[13]. In the present study, we established ectopic coex-
pression of Oct4 and Nanog 97 L-ON cell lines. We found
that 97 L-ON cells exhibited typical stem-like properties,
such as sphere formation ability, anchorage-independent
growth, chemotherapy resistance, and high tumorigenicity.
More strikingly, ectopic coexpression of Oct4 and Nanog
encouraged EMT in HCC, promoted migration and inva-
sion during HCC metastasis. Further molecular mechan-
ism revealed that Oct4/Nanog targeted Stat3 pathway inHCC and regulated the expression and function of Snail,
thus promoted EMT in HCC.
Self-renewal and chemoresistance are two important
characteristics of CSCs. To test whether Oct4/Nanog initi-
ate self-renewal properties in HCC, we performed colony
formation ability assay and sphere-forming ability assay
in vitro and tumorigenecity assay in vivo. Our study dem-
onstrated that overexpression of Oct4 and Nanog signifi-
cantly promoted self-renewal capacity of 97 L HCC cell
lines (Figure 1 and Table 1). Specifically, coexpression of
Oct4 and Nanog increased the expression of stem cell
markers CD133, ALDH1, and BMi-1. In addition, exogen-
ous Oct4 and Nanog expression substantially enhanced
the expression of ABCG2 and MDR1, two major ABC
transporters which attribute to drug resistance. To further
assess whether 97 L-ON cells possess a hypothesized CSC
chemoresistant property, we examined the sensitivity of
97 L-ON cells to chemotherapeutics. The results sug-
gested that 97 L-ON cells exhibited general resistance to
DDP, compared with its control cells. Although the under-
lying molecular mechanism of Oct4 and Nanog on CSCs
drug resistance is unclear, it manifested that stem cell
Figure 6 Silencing Stat3 dampens EMT phenotype and attenuates invasion/metastatic ability of 97 L-ON cells in vitro and vivo.
(A) 97 L-ON, mesenchymal, fibroblast-like cancer cells underwent morphologic change into epithelial phenotype after knockdown Stat3.
(B) Representative photographs of cell migration and invasion. (C) Quantification migration and invasion assay indicated that the numbers of
migrated or invaded 97 L-ON-shStat3 cells were less than those of 97 L-ON-Scramble cells (P < 0.001). (D) Significant decreases in the mesenchymal
genes, N-cadherin, Snail, and Vimentin and increase in the epithelial gene E-Cadherin were found in 97 L-ON-shStat3 cells by Western blot analysis.
(E) Up panel, representative photographs of intrahepatic invasion (H & E staining, black arrows point to the invasive nodules, ×100 magnification).
Bottom panel, representative photographs of lung metastasis (H & E staining, black arrows point to the metastatic nodules, ×40 magnification).
(F) Quantification analysis showed the numbers of liver dissemination (up panel) and lung metastasis (bottom panel) of 97 L-ON-shStat3 cells
were both less than those of 97 L-ON-Scramble cells (P = 0.003 and P = 0.001).
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ing cancer cells and preventing tumor recurrence in
current chemoradiation therapy.
The expression of Oct4 or Nanog has been reported in
the cancer stem-like cells and associated with a more
primitive and aggressive tumor phenotype [19]. Consist-
ent with previous studies, we found that ectopic overex-
pression of Oct4 and Nanog converted 97 L cellular
morphology to a fibroblast-like morphology (EMTchange).
Further cell proliferation assay, wound healing, and trans-
well assay indicated that Oct4/Nanog increased 97 L cell
proliferation, invasion, and metastasis in vitro. More
importantly, in vivo xenograft tumorigenicity, tumor inva-
sion, and metastasis assays confirmed that Oct4/Nanog
contributed to HCC intrahepatic dissemination and lungmetastasis. Therefore, it is conceivable that the core tran-
scriptional regulatory factor Oct4 and Nanog played an
important role in promoting tumorigenesis, invasion/me-
tastasis in HCC.
In the present study, we identified that Stat3 activation
played a mechanistic role in Oct4/Nanog-induced EMT
and cell invasion in HCC. Actually, biological function
between Oct4, Nanog, and Stat3 has been explored in
previous study. In embryonic stem cells, it has been shown
that Oct4 is essential for antiapoptotic effects in response
to stress, and these effects may be mediated through the
activation of Stat3 pathway [15]. More interestingly, Nanog
can form a complex with the p-Stat3, leading to Stat3-
specific transcriptional activation in breast and ovarian
tumor cells [16]. Using Oct4/Nanog overexpressing, as well
Yin et al. Journal of Hematology & Oncology  (2015) 8:23 Page 10 of 13as knockdown in HCC cell lines, we showed that in HCC,
Oct4 mediated Stat3 activation while Nanog mediated
p-stat3 nuclear translocation and binding to the Snail
promoter. Our findings suggested that targeting Oct4/
Nanog-mediated Stat3 signaling pathway may represent
a novel approach to overcome EMT process in liver
cancer cells displaying stem cell marker properties
during tumor progression.
Snail is one of the best-characterized E-cadherin gene
repressors required for triggering EMT. It represses E-
cadherin transcription by binding to the E-box site in the
promoter of E-cadherin [20]. In addition to its role in the
repression of E-cadherin, Snail is also known to stimulate
mesenchymal gene transcription such as N-cadherin and
Vimentin expressions [21]. We found that Oct4/Nanog-
mediated Stat3 activation is highly important for Snail
expression in HCC. The mRNA and protein levels of
Snail were increased upon Oct4/Nanog-mediated Stat3
activation and significantly decreased by the inhibition
or knockdown of Stat3 expression (Figure 5B, C). Re-
sults of the ChIP assay (Figure 5E) further supported
the regulatory role of Oct4/Nanog/Stat3 signaling on
Snail promoter. This result is consistent with another
report, which showed that Snail expression is regulated
by Stat3 signaling pathway in breast cancer during epi-
thelial mesenchymal transition [22]. It provides a mech-
anistic explanation for the prognostic studies that have
directly linked Oct4/Nanog [13], Stat3 signaling [23],
and Snail [24] with tumor recurrence, tumor metastasis,
and poor survival in HCC patients.
Increasing evidence shows a direct link between the
EMT and CSCs. Both EMT and CSC are implicated in
the generation of invasive cells and formation of distant
metastases. Furthermore, CSCs have been found to
express EMT-associated genes in addition to stemness-
associated genes. However, there is still a lack of evi-
dence to explain the biological similarities between
CSCs and EMT-phenotypic cancer cells. To the best of
our knowledge, this is the first report to illustrate how
stemness transcription factor Oct4 and Nanog regulates
EMT signaling in HCC.
Our study indicates a potential link between Oct4/
Nanog and Stat3/Snail signaling. This model of signaling
regulation between CSC characteristics and EMT path-
way may partially explain how cancer stem cells main-
tain their aggressiveness in the long period of time when
invading and migrating to surrounding tissues.
Taken together, our results provide novel insight into
the role of stem cell genes Oct4/Nanog in promoting
CSC-like traits and EMT change in HCC. As Oct4/Nanog
is actively involved in EMT process via regulation on
Stat3/Snail pathway, we postulate that inhibition of Stat3
pathway would be a promising therapeutic strategy to
control stem cells-associated EMT phenotype in HCC.Methods
Cell culture and transfection
MHCC97-L (97 L), a low-metastatic human HCC, was
established at our institution [25]. HepG2 cells were pur-
chased from the Shanghai cell bank, Chinese Academy
of Sciences. Human Oct4, and Nanog genes were PCR
amplified from normal genomic DNA and cloned into
lentiviral vector pGMLV-PA6 (Genomeditech Co., Ltd.,
Shanghai, China) for ectopic expression of Oct4 and
Nanog. Primers used for Oct4 and Nanog amplification
were listed in Additional file 3: Table S1. Oct4, Nanog,
or mock vectors were transfected into 97 L cells using
Lipofectamine 2000 reagent (Invitrogen, Carlsbad, CA,
USA). The transfected cells were selected under 3 μg/
mL puromycin (P8833, Sigma-Aldrich, St. Louis, MO,
USA). Clones of stably transected cells were obtained by
the limited dilution method. Cells with coexpression of
Oct4 and Nanog were named as 97 L-ON cells and the
expression of Oct4 and Nanog was confirmed by qRT-
PCR and Western blot analysis.
To generate plasmids that express specific short hair-
pin RNA, three sequences of shRNA targeting Oct4,
Nanog, and Stat3 were designed and cloned into cloning
vector pGMLV-SC1 (Genomeditech Co., Ltd.). The best
knockdown shRNA sequences were listed in Additional
file 3: Table S1. The sequence of Scrambled RNA was
used to generate the negative control. HCC cells trans-
fected with the lentiviral particles were selected with
3 μg/mL puromycin.
Real-time PCR and Western blot
Real-time RT-PCR procedures were performed according
to the manufacturer’s instructions. The primers for ampli-
fication of human genes were present in Additional file 3:
Table S1. Western blots were performed as described pre-
viously [26]. Abs against Oct4 (Cat. #ab19857) and Snail
(Cat. #ab180714) were brought from Abcam (AbCam,
Cambridge, UK). Abs against Nanog, total Stat3 (Cat.
#9139), p-Stat3Tyr705 (Cat. #9145), p-Stat3Ser727 (Cat.
#9130), Jak1 (Cat. #3332), p-Jak1 (Cat. #3331), Jak2
(Catalog: #3230), p-Jak2 (Cat. #3771), Src (Cat. #2108),
p-Src (Cat. #2105), and Histone H2A (Cat. #2578) were
brought form Cell Signaling Technology (Cell Signaling
Technology, Danvers, MA, USA). Abs against E-cadherin
(Cat. # sc-7870), N-cadherin (Cat. #sc-7989), Slug (Cat.
#sc-15391), Twist (Cat. #sc-15393), and Vimentin (Cat. #
sc-5565) were purchased from Santa Cruz Biotechnology
(Santa Cruz Biotechnology, CA, USA). Ab against GAPDH
(Cat. # KC-5G4) was from Kangcheng (Kangcheng Tech-
nology, Shanghai, China).
Cell proliferation assay
The measurement of cell proliferation was performed
with Cell Counting Kit-8 (Dojin Laboratories, Kumamoto,
Yin et al. Journal of Hematology & Oncology  (2015) 8:23 Page 11 of 13Japan). Cells (2 × 103 cells/well) were seeded in 96-well
plates and continuously incubated for 2 h with Cell
Counting Kit-8 solution. The absorbance of sample taken
from each well was measured on a spectrophotometer
(Thermo Electron, Andover, USA) at 450 nm. The re-
sults were plotted as the mean ± SD from three separate
experiments with six replicates per experiment for each
experimental condition.Colony formation assay
Cells were plated at a concentration of 1.5 × 103 cells in
60-mm2 culture dishes and cultured for 7 days, then
fixed with methanol and stained with 0.5% crystal violet
for 15 min. The dishes were photographed, and the col-
onies were counted.Spheroid body-forming assay
Cells were counted and seeded at 2,000 cells/well in a 96
well ultra-low-attachment plate (Corning Incorporated,
Corning, NY, USA) and cultured with DMEM-F12
medium supplemented with 2% B-27 supplement (Invi-
trogen), 20 ng/ml human bFGF, and 20 ng/ml EGF
(Chemicon, Temecula, CA, USA). Once spheres began
to form, they were quantified using inverted contrast mi-
croscopy (Leica DMI 3000B, Wetzlar, German) by count-
ing the number of spheres per culture well.Wound healing assay
Cells were cultured for 2 days to form a tight cell mono-
layer and then serum-starved for 16 h. After the serum
starvation, the cell monolayer was wounded with a 10 μl
plastic pipette tip. At the indicated times, migrating cells
at the wound front were photographed. A percentage of
the wound area at each time point was measured using
Image-Pro Plus v6.2 software.Transwell assay
The migration or invasion assays were carried out using
transwell chamber with 6.5-mm diameter polycarbonate
filters (8 μm pore size, BD Biosciences, Erembodegem,
Belgium) coated with or without matrigel. Cells (5 × 104)
in serum-free media were seeded in the top chamber
and 20% FBS was used as the chemoattractant in the
bottom chamber. After incubation for 24 h, all of the
non-invaded (or non-migrated) cells were removed, and
cells that have invaded (or migrated) through the mem-
branes were fixed with methanol, stained with Giemsa
stain. Quantification of the invaded (or migrated) cells
was done by counting four regions of the filter under
the microscope. Triplicate filters were used and the
experiments were repeated three times.In vivo xenograft tumorigenicity, tumor invasion, and
metastasis assays
Male athymic BALB/c nude mice were purchased from
Shanghai Institute of Material Medicine, Chinese Academy
of Science, and were raised in specific pathogen-free condi-
tions. Animal care and experimental protocols were con-
ducted in accordance with guidelines established by the
Shanghai Medical Experimental Animal Care Commission.
For in vivo tumorigenicity experiments, 97 L-ON cells
or 97 L-Ctrol cells (5 × 103, 5 × 104, 5 × 105, respectively)
were injected subcutaneously into the right flank of each
mouse (six mice per group). The mice were observed for
tumor growth every day over 6 to 8 weeks and then
sacrificed by cervical dislocation.
For in vivo tumor invasion and lung metastasis assays,
5 × 106 97 L-ON Cells and 97 L-Ctrl cells were subcuta-
neously inoculated into the right flanks of the nude
mice. After 6 weeks, subcutaneous tumors were surgi-
cally excised, weighed, and photographed. Nonnecrotic
tumor tissue was cut into 1-mm3 pieces and orthotopi-
cally implanted into the liver. Intrahepatic dissemination
and lung metastasis were determined by pathological
examinations.
Immunofluorescence staining
Briefly, cells cultured on glass slides were fixed by 4%
paraformaldehyde. The slides were incubated with pri-
mary antibodies against Nanog, p-Stat3Tyr705 for 1 h and
followed by the secondary antibodies Alexa Fluor®488 goat
anti-rabbit and Alexa Fluor®568 goat anti-rabbit IgG
(1:800 dilution; Invitrogen) for 1 h. Nuclei were stained
with DAPI (Invitrogen). Fluorescent images were visual-
ized using a confocal laser scanning microscope (FV-1000;
Olympus Tokyo, Japan).
Co-immunoprecipitation analysis
Immunoprecipitation was performed with 97 L cells and
HepG2 cells. The interaction between Nanog and p-
Stat3 was analyzed. Cells were plated in 100-mm2 dishes
(1.5 × 106/dish) and were harvested with lysis buffer. A
quantity of 4 mg of protein was mixed with 40 μl of Pro-
tein A-Sepharose beads (Sigma) in the immunoprecipita-
tion assay buffer, incubated at 4°C for 2 h with gentle
agitation and centrifuged for 10 min at 2,000 rpm for
preclearing. The recovered supernatant was incubated
with 2 μg of anti-Nanog (1:1,000) or anti-phospho-Stat3
Try705 antibody (1:1,000) in the presence of protease
inhibitors at 4°C overnight. Then 50 μl of Protein A-
Sepharose beads was added, and the incubation was con-
tinued for 2 h at 4°C with gentle shaking. The Protein
A-precipitated protein complex was recovered by a brief
centrifugation followed by three washes with the immu-
noprecipitation assay buffer. The harvested beads were
resuspended in 30 μl of 2 × SDS PAGE sample buffer
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20 μg aliquot of cell lysate was used as an input control.
The samples were analyzed by Western blot.
Chromatin immunoprecipitation
Chromatin immunoprecipitation assay was performed using
a Chromatin Immunoprecipitation Assay Kit (Millipore,
Billerica, MA, USA) according to the manufacturer’s
instructions. Immunoprecipitations were preformed with
anti-pStat3 or mouse IgG (Cell Signaling Technology) as a
negative control. Immunoprecipitated DNA was analyzed
by real-time PCR with SYBR Green. The resulting PCR
product which spans the −592 to −301 region of Snail pro-
moter includes the putative Stat3-binding sites. Specific
sequences of the human Snail promoter in the immuno-
precipitates were detected by PCR with primers forward
5′-CCCTCGGTGCTTC TTCACTT-3′ and reverse 5′-C
CAGAAAGTGCGATGATATGCA-3′.
Statistical analyses
All experiments were repeated at least three times and
representative results are presented. All values in the
figures and text are the means ± SD. Statistical analyses
were performed using the SPSS 13.0 for Windows (SPSS,
Inc., Chicago, IL, USA). Any significant differences
among mean values were evaluated by Student t test or
Mann–Whitney U test. A two-sided P < 0.05 was ac-
cepted as significant.
Additional files
Additional file 1: Figure S1. Inhibition of Jak2 activation in 97 L-Oct4
cells by Jak2 inhibitor AZD1480. 97 L-Oct4 cells were treated with 0, 1.0,
2.5, 5, 10 μmol/L AZD1480 and, respectively, for 48 h. Inhibition of p-Jak2
by AZD1480 abrogated Oct4-induced phosphorylation of Stat3 and its
downstream genes CyclinD1 and Survivin.
Additional file 2: Figure S2. Immunoprecipitation assay confirmed
Nanog interacts with p-Stat3 (Y-705) in the nucleus of HepG2 cell line.
Equal amounts of protein were immunoprecipitated (IP) with an
anti-Nanog monoclonal antibody or anti-p-Stat3-Y705 antibody and were
immunoblotted to detect Nanog or p-Stat3 (Y-705). Normal mouse IgG
was used as a control antibody.
Additional file 3: Table S1. Sequences for and shRNAs and primers for
gene amplification in this study.
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